• Carl Icahn takes proxy fight to Illumina: report

    17 days ago - By San Diego Biotechnology

    A proxy fight is brewing at Illumina as activist investor Carl Icahn readies for an argument that the DNA sequencer is costing shareholders billions by following through with its Grail purchase. The Wall Street Journal...
    Read more ...